This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for female infertility, announced today the appointment of Hugh Taylor, M.D., the Anita O'Keeffe Young Professor of Obstetrics, Gynecology, and Reproductive Sciences and Professor of Molecular, Cellular, and Developmental Biology at the Yale School of Medicine and Chief of Obstetrics and Gynecology, Yale-New Haven Hospital, to its Scientific Advisory Board. OvaScience also established a research collaboration with Dr. Taylor to develop potential new treatments and diagnostic markers for endometriosis, a leading cause of female infertility.
“Dr. Taylor is a world expert and pioneer in the field of endometriosis, a disease that is frequently misdiagnosed and lacking in new treatment options for patients,” said Arthur Tzianabos, Ph.D., Chief Scientific Officer of OvaScience. “We look forward to working with Dr. Taylor to develop new methods for treating and diagnosing this leading cause of female infertility.”
Dr. Taylor has more than 25 years of experience as a clinician and researcher in reproductive medicine. His research focuses on stem cells, uterine development and endometriosis, work that has led to the publication of more than 125 articles. He is currently Editor-in-Chief of
Reproductive Sciences. In 2013, Dr. Taylor was recognized by the IVI Foundation for producing the best research in reproductive medicine and in 2012, he was named Honoree of the Year by the Endometriosis Foundation. Dr. Taylor received his undergraduate training at Yale University and received his medical degree from the University of Connecticut School of Medicine. He completed his residency in Obstetrics and Gynecology at Yale. His postdoctoral training included a fellowship in Reproductive Endocrinology and Infertility as well as a fellowship in Molecular Biology, both at Yale.
“This work will help us continue to explore how endometrial stem cells and certain biomarkers of disease can be used to develop new treatments and potentially non-invasive diagnostics for endometriosis,” said Hugh Taylor, M.D., Professor of Obstetrics, Gynecology, and Reproductive Sciences and Professor of Molecular, Cellular, and Developmental Biology at the Yale School of Medicine and Chief of Obstetrics and Gynecology, Yale-New Haven Hospital. “Our research and OvaScience’s advances in its egg precursor cell technology platform offer exciting possibilities for helping patients who are experiencing the painful effects of endometriosis and infertility.”